Impact of Percutaneous Transvenous Mitral Commissurotomy on The Left

Status Not yet recruiting

Clinical Trial Summary

• Evaluation of the effect of PTMC on LAA function by TEE at least one month after the procedure and its effectiveness in prevention of thrombi formation and cerebrovascular complications.

Clinical Trial Description

- Mitral stenosis (MS) is a disabling disease that limits the normal physical abilities of patients and considered as a major reason for hospital admissions . The leading cause of MS globally is rheumatic heart disease(RHD), which remains common in economically developing countries and continues to be a significant cause of morbidity and mortality. - Chronic pressure and volume overload imposed by MS causes left atrial (LA) and Left Atrial Appendage (LAA) dysfunction leading to reduced blood flow velocities thereby producing stasis of blood, reduced LA and LAA ejection fraction and atrial fibrillation (AF). - These factors predispose to formation of LA and LAA thrombi in MS and result in thromboembolic episodes. Risk of cerebrovascular accident (CVA) is increased approximately five-fold in non-rheumatic AF and 17-fold in patients with MS with AF. Even patients of MS in sinus rhythm with depressed LA and LAA function are at increased risk of CVA. Assessment of LAA function is helpful in predicting the risk of thromboembolism . - PTMC can improve the function of the LAA by reducing the left atrial pressure and increasing the blood flow through the mitral valve. - Echocardiography, particularly transesophageal echocardiography (TEE), is currently the modality of choice for evaluation of the LAA. Transesophageal echocardiography (TEE) allows semi-invasive, highly accurate imaging of the functional efficiency of LAA by LAA Doppler and Doppler tissue imaging (DTI) . - MS causes decreased LAA Doppler and DTI velocities in patients even with sinus rhythm . So, this study aims to evaluate effect of successful PTMC on LAA function by TEE Doppler and DTI (doppler tissue imaging). - Fractional area change (FAC): The FAC is a measure of the percentage of change in the area of the LAA during systole. A higher FAC indicates a more contractile LAA. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06340997
Study type	Interventional
Source	Assiut University
Contact	Mohamed Ismail
Phone	01091806181
Email	prep.ismail@gmail.com
Status	Not yet recruiting
Phase	N/A
Start date	July 1, 2024
Completion date	August 1, 2027

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06167213` - ALLIANCE Mitral: Safety and Effectiveness of SAPIEN X4 Transcatheter Heart Valve - Mitral	N/A
Completed	`NCT02188862` - Genetic Susceptibility to Rheumatic Heart Disease in the Pacific Region	N/A
Recruiting	`NCT04045093` - Dabigatran for Mitral Stenosis Atrial Fibrillation	Phase 4
Recruiting	`NCT05625607` - Polish Transcatheter Transfemoral Mitral Valve-in-Valve Implantation (Mitral ViV) Registry
Not yet recruiting	`NCT06067815` - Assessment of Right Ventricular Function in Patients With Severe Mitral Stenosis Before and After Balloon Mitral Valvuloplasty
Completed	`NCT01022463` - Effect of Ivabradine on Heart Rate & Effort Tolerance in Mitral Stenosis in Sinus Rhythm	Phase 3
Terminated	`NCT03926156` - RIvoraxaban in Mitral Stenosis	Phase 3
Not yet recruiting	`NCT06377449` - Influence of Lung Ultrasonography on the Prognosis and Postoperative Outcomes in Cardiac Surgical Patients	N/A
Recruiting	`NCT04408430` - The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).	N/A
Active, not recruiting	`NCT06191718` - Clinical Investigation for the Foldax Tria Mitral Valve- India	N/A
Recruiting	`NCT03991910` - The Effect of Ramipril in Suppressing ST2 Expression in Rheumatic Mitral Stenosis Patients	Phase 3
Completed	`NCT02783248` - French National Observatory of Percutaneous Mitral Commissurotomy
Recruiting	`NCT05925335` - The China Mviv Registry	N/A
Completed	`NCT02502448` - Acute Normovolemic Hemodilution on ROTEM in Cardiac Surgery	N/A
Completed	`NCT04527367` - Epidemiology and Long-term Outcome of Patients With VHD
Active, not recruiting	`NCT05526560` - Real-world Clinical Outcomes of the MITRIS RESILIA Mitral Valve
Completed	`NCT06371222` - Role of Ivabradine on Heart Rate and Quality of Life in Patients With Mitral Stenosis in Sinus Rhythm	Phase 4
Completed	`NCT02831270` - Acute Normovolemic Hemodilution on Serum-creatinine Concentration in Cardiac Surgery	N/A
Recruiting	`NCT01270750` - Bosentan for Severe Mitral Valve Dysfunction	Phase 1/Phase 2
Active, not recruiting	`NCT01757665` - ProspeCtive, nOn-randoMized, MulticENter Clinical Evaluation of Edwards Pericardial Bioprostheses With a New Tissue Treatment Platform (COMMENCE)	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Impact of Percutaneous Transvenous Mitral Commissurotomy on The Left Atrial Appendage Function in Patients With Mitral Stenosis.

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms